TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

Beacon Therapeutics, a clinical-stage biotechnology company focused on ocular gene therapies, announced a Series C funding round of over $75 million led by Life Sciences at Goldman Sachs Alternatives, with participation from the Retinal Degeneration Fund. The funds will support commercialization of laru-zova for X-linked retinitis pigmentosa treatment, with pivotal trial data expected in H2 2026, and advance development of pipeline candidates for geographic atrophy and inherited cone rod dystrophy.

Insights
GS   positive

Goldman Sachs' Life Sciences division led the Series C round and appointed a Managing Director to Beacon's Board, signaling confidence in the company's strategy and potential for value creation in the gene therapy space.